Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.

Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.

Item

http://www.wikidata.org/entity/Q33364342

Q33364342

about

Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a clinical practice guideline.Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Pharmacological therapies for Liposarcoma.Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.Multivariate Markov models for the conditional probability of toxicity in phase II trials.Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma.Managing sarcoma: where have we come from and where are we going?Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue.Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy.Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma G

P2860

Q24234049-2AF92DD9-95F2-4CC9-8C37-C76E2AC428D8 Q33379481-39A40229-562A-4F61-8C97-D6571D6056CF Q33406493-ECFC3EF4-156E-4D25-9571-45FA65B6D6D5 Q35214578-21B20647-EED5-4B05-A06C-F653F65BD8B7 Q35220462-E856D34D-2C85-496C-821A-0A7E172CDF40 Q36191321-B3F0D74C-EC05-49DC-ABDA-C1A20AB57CA0 Q36611978-C8B1FAF8-256A-4D6F-9A33-764D4569A1EA Q36731032-90246D53-5B83-4BBA-9110-BAD8A20D85C3 Q37330372-E912AADB-37CD-451D-B557-250A249C2635 Q37886394-0BD5D6E2-116D-4036-A74B-D29464FBDB41 Q38797843-B4DF00B0-C510-47A0-8671-5957A9F96F83 Q38991731-2B6384A0-8035-4BB2-A710-11D9A3420805 Q39743562-65FDE496-FB00-42A2-A2DA-BB2574C3CEEA Q40650639-3AD8B0F7-66B5-413F-8739-A7437C727F2E Q41963479-B7FBB3FC-E8E4-4F23-9767-FEFCD47EECC2 Q41988197-E9FA9E16-F97A-4FF9-B9C5-2E8725168720 Q49627984-B7AA764D-A7AC-472B-8B7C-04D4B96347DC Q55350018-80CD493A-702F-4D1E-9B53-5964F4A1CFDB Q57570892-406DE874-EF5C-4BB7-A3A5-A1DBBB5427E9

P2860

Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.

Item

http://www.wikidata.org/entity/Q33364342

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu